Biotech company PharmaCyte Biotech (OTCMKTS:PMCBD), focused on developing cellular therapies for cancer and diabetes, on July 13 announced that post storage for 3 years, the original cytochrome P450 expressing cells from PharmaCyte’s Master Cell Bank (MCB) manufactured by Eurofins Lancaster Laboratories still have excellent enzymatic activity and viable, elements critical for stability. The study is …